ANI ‘On The Cusp Of A Transformation’ Following Cortrophin Launch
Company Expects Up To $40m From The Product In 2022
ANI Pharmaceuticals appeared confident about its Cortrophin gel launch and integration of Novitium Pharma as it rounded up its Q1 results, but net losses have dampened the company’s share value.
You may also be interested in...
Successful Cortrophin Gel Launch Could Drive Growth At ANI For Years To Come
The launch of ANI Pharmaceutical’s Cortrophin gel has reignited interest in the ACTH drug category, and appears set to drive growth at the company for the foreseeable future.
ANI Plans To Shutter Oakville Plant By Q1 2023
ANI Pharmaceuticals has announced the closure of its Oakville, Ontario manufacturing plant, a move which is expected to save the firm $7m to $8m.
ANI Delivers On Cortrophin Gel US Launch
ANI Pharmaceuticals has finally delivered its long-awaited launch of purified Cortrophin Gel (repository corticotropin injection) in the US, accompanying the launch with its ‘Cortrophin In Your Corner’ dedicated program to increase access and provide reimbursement support.